Group II muscle afferents probably contribute to the medium latency soleus stretch reflex during walking in humans.
1. The objective of this study was to determine which afferents contribute to the medium latency response of the soleus stretch reflex resulting from an unexpected perturbation during human walking. 2. Fourteen healthy subjects walked on a treadmill at approximately 3.5 km h(-1) with the left ankle attached to a portable stretching device. The soleus stretch reflex was elicited by applying small amplitude (approximately 8 deg) dorsiflexion perturbations 200 ms after heel contact. 3. Short and medium latency responses were observed with latencies of 55 +/- 5 and 78 +/- 6 ms, respectively. The short latency response was velocity sensitive (P < 0.001), while the medium latency response was not (P = 0.725). 4. Nerve cooling increased the delay of the medium latency component to a greater extent than that of the short latency component (P < 0.005). 5. Ischaemia strongly decreased the short latency component (P = 0.004), whereas the medium latency component was unchanged (P = 0.437). 6. Two hours after the ingestion of tizanidine, an alpha(2)-adrenergic receptor agonist known to selectively depress the transmission in the group II afferent pathway, the medium latency reflex was strongly depressed (P = 0.007), whereas the short latency component was unchanged (P = 0.653). 7. An ankle block with lidocaine hydrochloride was performed to suppress the cutaneous afferents of the foot and ankle. Neither the short (P = 0.453) nor medium (P = 0.310) latency reflexes were changed. 8. Our results support the hypothesis that, during walking the medium latency component of the stretch reflex resulting from an unexpected perturbation is contributed to by group II muscle afferents.
Grey
M J
MJ
Center for Sensory-Motor Interaction, Aalborg University, Fredrik Bajersvej 7-D3, DK-9220, Aalborg, Denmark. mg@smi.auc.dk
Ladouceur
M
M
Andersen
J B
JB
Nielsen
J B
JB
Sinkjaer
T
T
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000328:Adult; D000779:Anesthetics, Local / Q000494:pharmacology; D000842:Ankle; D003000:Clonidine / Q000031:analogs & derivatives / Q000494:pharmacology; D003080:Cold Temperature; D004576:Electromyography; D005260:Female; D005528:Foot; D006801:Humans; D007511:Ischemia / Q000503:physiopathology; D008012:Lidocaine / Q000494:pharmacology; D008297:Male; D018482:Muscle, Skeletal / Q000098:blood supply / Q000294:innervation* / Q000502:physiology*; D009475:Neurons, Afferent / Q000187:drug effects / Q000502:physiology*; D011930:Reaction Time / Q000502:physiology; D012026:Reflex, Stretch / Q000502:physiology*; D013997:Time Factors; D016138:Walking / Q000502:physiology*
D000316:Adrenergic alpha-Agonists; D000779:Anesthetics, Local; C023754:tizanidine; D008012:Lidocaine; D003000:Clonidine